miR-101 sensitzes human nasopharyngeal carcinoma cells to radiation by targeting stathmin 1

QUANQUAN SUN*, TONGLIN LIU*, TIAN ZHANG, SHASHA DU, GUOZHU XIE, XIAOSHAN LIN, LONGHUA CHEN and YAWEI YUAN

Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510515, P.R. China

Received April 14, 2014; Accepted August 6, 2014

DOI: 10.3892/mmr.2015.3221

Abstract. Radioresistance remains a major problem in the treatment of patients suffering from nasopharyngeal carcinoma (NPC). A better understanding of the mechanisms involved in the induction of radioresistance may provide strategies to improve NPC patients’ response to therapy. The present study aimed to investigate the effect of microRNA (miR)-101 on the radioresistance of NPC cells. Analysis of miR-101 expression levels indicated that miR-101 was downregulated in NPC cell lines. Furthermore, ectopic expression of miR-101 suppressed cell proliferation and enhanced radiosensitivity of NPC cells. Stathmin 1 (STMN1) was additionally verified as a direct functional target of miR-101, which was found to be involved in cell viability, radioresistance and radiation-induced autophagy of NPC cells. In conclusions, the results of the present study suggested that the identified miR-101/STMN1 pathway contributed to the elucidation of the mechanisms of radioresistance in human NPC and that it may represent a potential therapeutic target.

Introduction

Nasopharyngeal carcinoma (NPC) is one of the most common types of cancer derived from epithelial cells located in the nasopharynx (1). NPC has a distinct epidemiology and distribution, with the highest incidence in southern China and Southeast Asia (2). Radiotherapy is the primary therapeutic strategy for patients with NPC (3). Although numerous patients with NPC undergo radiotherapy treatment, advanced NPC patients tend to experience therapy failure due to local recurrence and distant metastasis (4). The poor prognosis of NPC patients may be due to its radioresistance (5). An improved understanding of the molecular mechanisms that contribute to the radioresistance of NPC may provide novel therapeutic strategies and therefore improved clinical outcomes.

MicroRNAs (miRNAs) are a class of small (19-25 nucleotides) endogenous non-coding RNA molecules that regulate gene expression at the post-transcriptional level by translational arrest or messenger RNA (mRNA) cleavage. These effects are achieved via miRNA-binding to the 3' untranslated region (3'UTR) of their target mRNA, which decreases expression of the associated protein (6). An increasing body of evidence suggests that miRNAs have crucial roles in numerous biological processes, including cellular differentiation, proliferation, apoptosis, autophagy and metabolism (7,8). The dysregulation of miRNAs may be associated with numerous human diseases, including certain types of cancer (9). Specific miRNAs function as tumor suppressors or oncogenes and are influential in tumor progression and therapeutic resistance (10). Of note, recent studies have indicated an association between the expression of certain miRNAs, including miR-608 and miR-29c, and the success of radiotherapy treatment, particularly in NPC. (11,12). Further studies have indicated that miR-101 is downregulated in numerous types of cancer, including gastric (13), lung (14) and colon cancer (15), and a loss of miR-101 expression is involved in carcinogenesis (16) and angiogenesis (17). Studies have also indicated that the ectopic expression of miR-101 is able to sensitize non-small cell lung cancer cells to radiation by targeting DNA-dependent protein kinase and ataxia telangiectasia mutated (ATM) (18). However, the association between miR-101 and the modulation of radiosensitivity in NPC remains to be elucidated.

The present study aimed to elucidate the function of miR-101 in NPC by analyzing miR-101 expression in NPC cell lines and investigating the effects of ectopic expression on NPC-cell proliferation and radiosensitivity. Additionally, the present study aimed to identify functional targets of miR-101 in order to elucidate the mechanism by which it exerts its effects in NPC and thereby propose a strategy for enhancing NPC cell radiosensitivity and improving treatment of NPC.

Correspondence to: Professor Yawei Yuan, Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, 1838 Guangzhou Great Road, Guangzhou, Guangdong 510515, P.R. China
E-mail: yuanyw66@aliyun.com

*Contributed equally

Key words: microRNA, nasopharyngeal carcinoma, radioresistance, miR-101, stathmin 1
Materials and methods

Cell culture. Three NPC cell lines (CNE-2, 5-8F and 6-10B) were provided by Prof. Xia Yunfei (Sun Yat-sen University Cancer Center, Guangzhou, China) and maintained in the State Key Laboratory of Oncology in South China (Guangzhou, China). The CNE-1 and NP69 cell lines were maintained in the lab at Nanfang Hospital, Southern Medical University (Guangzhou, China) and were purchased from the Cell Bank of Sun Yat-Sen University in 2010. The passage number of all five cell lines used in the present study was <20. All of the cell lines were tested against mycoplasma infection. CNE-1, CNE-2, 5-8F and 6-10B cells were maintained in RPMI-1640 medium (Invitrogen Life Technologies, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum (FBS; Invitrogen Life Technologies), 100 U/ml penicillin (Sigma-Aldrich, St. Louis, MO, USA) and 50 μg/ml streptomycin (Sigma-Aldrich). NP69 cells were cultured in keratinocyte-serum-free medium (Invitrogen Life Technologies) supplemented with bovine pituitary extract (BD Biosciences, San Jose, CA, USA). All cell lines were incubated at 37°C in a humidified atmosphere of 5% CO₂.

Quantitative polymerase chain reaction (qPCR). Total RNA was isolated from cells using Trizol reagent (Invitrogen) according to the manufacturer's instructions. The reverse-transcription and PCR primers for miR-101 and U6 were purchased from Ribobio (Guangzhou, China). The PCR primers for STMN1 were forward, 5'-CCTCTGGTTGGCGCTTTTGTGC-3' and reverse, 5'-GGCACGCTTCAGTCTTCCAC-3'. The PCR primers for β-actin were forward, 5'-TCGACAAAGCTCGCTGGC-3' and reverse, 5'-AAGGATGCTGGTCCAGATTTTC-3'. The cDNA library was synthesized using the PrimeScript RT reagent kit (Takara Bio, Inc., Dalian, China). For mature miRNA quantification, cDNA was generated using specific stem-loop universal primers. Aliquots of cDNA were amplified for 40 cycles, which were performed as follows: Denaturing at 95°C for 5 sec, annealing at 60°C for 34 sec and extension at 60°C for 1 min. Real-time qPCR for miRNA and mRNA was performed using SYBR® Premix Ex Taq II (Takara) and quantified in an ABI 7500 Sequence Detection system (Perkin Elmer/Applied Biosystems). Either U6 or β-actin were used as an internal control.

Oligonucleotide and small interfering RNA (siRNA) transfection. miR-101 mimic, miRNA mimic negative control oligonucleotides, STMN1 siRNA and siRNA negative control were all purchased from Ribobio. Oligonucleotide and siRNA transfection were performed using Lipofectamine® 2000 reagent (Invitrogen) according to the manufacturer’s instructions.

Cell proliferation assay. Cell proliferation was measured using the MTT dye reduction method (19). Briefly, 48 h following transfection, cells were seeded in 96-well plates at a low density (2x10³ cells/well) in RPMI-1640 medium supplemented with 10% FBS and incubated for 1-5 days. Following incubation, 50 μl MTT solution (2 mg/ml; Sigma-Aldrich) was added to each well, and the cells were incubated for a further 2 h at 37°C. The media containing MTT solution was removed, and the dark blue crystals were dissolved by the addition of 100 μl dimethylsulfoxide. The absorbance value was measured with a microplate reader (SpectraMax M5; Molecular Devices, Sunnyvale, CA, USA) at a test and reference wavelength of 570 nm. The percentage of growth was determined relative to untreated controls. Each experiment was performed ≥three times with triplicate samples.

Clonogenic survival assays. CNE-2 and 5-8F cells were pretreated by either miR-101 mimic or STMN1 siRNA transfection for 48 h and subsequently seeded onto six-well plates in triplicate at specific cell densities, followed by exposure to the indicated doses of radiation (0, 2, 4, 6 or 8 Gy) using 6 MV X-rays generated from linear accelerators (Varian 2300EX; Varian, Palo Alto, CA, USA) at a dose rate of 3 Gy/min. Following 10-14 days of incubation at 37°C, the cells were fixed using 100% methanol and stained using 1% crystal violet (Sigma-Aldrich). Colonies containing ≥50 normal-appearing cells were counted via microscopic inspection (Olympus IX71; Olympus, Tokyo, Japan). The surviving fraction was calculated as described previously (20). The multi-target single-hit model was fitted to the data to generate survival curves using the formula: SF=1-(1-e^(-D/D0))². The sensitization enhancement ratio at a survival fraction of 10% (SER10) was subsequently calculated. Each experiment was independently performed ≥three times.

Immunofluorescent staining for γ-H2AX. Forty-eight hours following transfection with miR-101 mimic or miRNA mimic negative control, 1x10⁵ cells were seeded in chamber slides and incubated overnight. The cells were subsequently exposed to 6 Gy irradiation (IR). Twenty-four hours following IR, the cells were fixed in 4% paraformaldehyde (Sigma-Aldrich), permeabilized in 0.1% Triton X-100 (Sigma), blocked in 2% bovine serum albumin (Roche, Stockholm, Sweden) and incubated with a primary antibody against γ-H2AX (Abcam, San Francisco, CA, USA) overnight at 4°C. The primary antibody was subsequently washed off, and a secondary antibody conjugated to fluorescein isothiocyanate (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA) was applied to the slides. Cells were washed with phosphate-buffered saline (Sigma-Aldrich) and counterstained with DAPI (Invitrogen Life Technologies). The γ-H2AX foci were observed under a fluorescence microscope (Olympus BX51, Olympus). For each group, the γ-H2AX foci were counted in ≥50 cells.

Antibodies and western blot analysis. For the western blot analysis, cells were lysed in radio-immunoprecipitation assay buffer (Cell Signaling Technology, Beverly, MA, USA) containing phosphatase and proteinase inhibitor cocktails (Sigma-Aldrich). The protein concentrations were determined using a bicinchoninic acid protein assay kit (Pierce Biotechnology, Rockford, IL, USA). Equal amounts of total protein were resolved via SDS-PAGE (Bio-Rad, Hercules, CA, USA), and the proteins were transferred onto polyvinylidene difluoride membranes (Bio-Rad). The membranes were blocked in 5% non-fat milk for 1 h at room temperature and then incubated overnight at 4°C with primary antibodies to anti-STMN1 (Abcam), anti-LC3B...
miR-101 is downregulated in NPC cell lines and affects the radiation response of NPC cells. In the present study, the expression of miR-101 in four NPC cell lines and the human immortalized nasopharyngeal epithelial cell line NP69 was investigated. As indicated in Fig. 1A, the miR-101 levels were significantly decreased in all four NPC cell lines (P<0.01), particularly in the 5-8F and CNE-2 cell lines.

The effects of radiation on miR-101 expression of NPC cells were also examined. As demonstrated in Fig. 1B, the levels of IR-induced miR-101 expression in both cell lines increased upon IR. These results indicated that miR-101 may influence the IR response of NPC cells.

miR-101 suppresses NPC-cell viability and sensitizes NPC cells to radiation. To evaluate the effects of miR-101 overexpression on the cell viability and radiosensitivity of NPC cells, an MTT assay and a clonogenic survival assay were performed following transfection of CNE-2 and 5-8F cells with miR-101 mimic or negative control. The ectopic expression of miR-101 significantly reduced the proliferation of NPC cells compared with that of the controls (Fig. 2A). Moreover, the survival fraction of cells transfected with miR-101 mimics was independently performed at three times.

Statistical analysis. All values were expressed as the mean ± standard deviation and were obtained from experiments that were repeated at least three times. Significant differences between the means were measured using a two-tailed unpaired Student’s t-test or one-way analysis of variance. All statistical analyses were performed using SPSS version 13.0 software (SPSS Inc., Chicago, IL, USA). P<0.05 was considered to indicate a statistically significant difference between values.

Results

miR-101 is downregulated in NPC cell lines and affects the radiation response of NPC cells.
SUN et al: miR-101 SENSITIZES NASOPHARYNGEAL CARCINOMA CELLS TO RADIATION

was significantly decreased following various doses of irradiation compared with that of cells transfected with negative controls (Fig. 2B).

To assess the effect of miR-101 on DNA damage in NPC cells, the number of γ-H2AX foci following IR was measured. The γ-H2AX foci-number is an established molecular marker of DNA damage and repair (21). As indicated in Fig. 2C, the ectopic expression of miR-101 led to a markedly increased persistence of γ-H2AX foci 24 h post-IR compared with that of the control groups. These results suggested that miR-101 enhanced the radiosensitivity of NPC cells in a manner that may be associated with the suppression of cell viability and persistence of DNA damage.

STMN1 is a direct target of miR-101 and is involved in NPC-cell radioresistance and growth. To investigate the molecular mechanism by which miR-101 increased the radiosensitivity of NPC cells, STMN1 was identified as a potential target of miR-101 based on the three publicly available databases [TargetScan (http://www.targetscan.org), miRanda (http://www.microrna.org/microrna/home.do) and Pictar (http://pictar.mdc-berlin.de)] and a previous study (7). The ectopic expression of miR-101 was able to significantly suppress the mRNA and protein expression of STMN1 (Fig. 3A and B). Subsequently, luciferase reporter vectors that contained wild-type or mutant miR-101 target sequences of the STMN1 3'UTR were constructed (Fig. 3C, lower panel) and a luciferase reporter assay was performed to determine whether STMN1 was a direct target of miR-101. It was demonstrated that the overexpression of miR-101 significantly suppressed the luciferase activity of the wt 3'UTR of STMN1 but not the mut reporter gene (Fig. 3C, upper panel), indicating the specificity of miR-101 to target the STMN1 3'UTR. These results indicated that STMN1 is a direct target of miR-101 in NPC cells.

To confirm that the miR-101-enhanced radiosensitivity is due to the direct targeting of STMN1, CNE-2 and 5-8F cells were transfected with STMN1 siRNA or control siRNA. Knocking down the expression of STMN1 significantly enhanced the radiosensitivity of CNE-2 and

Figure 2. miR-101 suppresses NPC cell viability and sensitizes NPC cells to IR. (A) Cell viability was determined following transfection with miR-101 mimic or miRNA mimic NC at day 1-5 in CNE-2 and 5-8F cells. (B) Clonogenic survival assays of CNE-2 and 5-8F cells treated with miR-101 mimic or miRNA mimic NC followed by various doses of irradiation. Surviving fractions were calculated as described. SER10, sensitizer enhancement ratio at 10% survival. (C) γ-H2AX foci formation was determined in CNE-2 and 5-8F cells transfected with miR-101 mimic or miRNA mimic negative control 24 h following IR. DAPI staining was performed and micrographs were captured at magnification x400. The median number of foci formation is presented in bar graphs. Values are presented as the median ± standard deviation. *P<0.05 vs. 6 Gy. miR. NPC, nasopharyngeal carcinoma; IR, irradiation; miR, microRNA; NC, negative control.
5-8F cells (Fig. 3D and E). Furthermore, the proliferation assay indicated that silencing STMN1 expression significantly suppressed CNE-2 and 5-8F cell growth (Fig. 3F). These data demonstrated that miR-101 enhanced radiosensitivity by directly targeting STMN1.

Restoration of STMN1 expression rescues the effect of miR-101 on cell viability, radiosensitivity and radiation-induced autophagy. To determine the functional relevance of STMN1 regulation by miR-101, the effect of STMN1 on miR-101-mediated growth suppression and radiosensitivity was evaluated. STMN1 expression was markedly increased following transfection with PCA-STMN1 plasmid (Fig. 4A). Furthermore, the co-expression of STMN1 markedly rescued the growth suppression and radiosensitivity of CNE-2 cells transfected with the miR-101 mimic (Fig. 4B and C). Additionally, forced expression of STMN1 rescued the downregulation of autophagy-associated protein LC3II and upregulation of p62 protein (Fig. 4D), and decreased the lipidation of LC3 (Fig. 4E), which represented decreased activity of autophagy in the presence of miR-101 24 h following irradiation. These results indicated that STMN1 is one of the key functional targets of miR-101, with respect to the effect of miR-101 on the growth inhibition, radiosensitivity enhancement and autophagy inhibition of NPC cells.

**Discussion**

The results of the present study demonstrated that miR-101 was downregulated in NPC cell lines and that IR induced the expression of miR-101. The ectopic expression of miR-101 suppressed the viability of, and enhanced the radiosensitivity of NPC cells. STMN1 was additionally identified as a direct functional target of miR-101 involved in cell growth,
SUN et al: miR-101 SENSITIZES NASOPHARYNGEAL CARCINOMA CELLS TO RADIATION

3335

Radiosensitivity and radiation-induced autophagy. These results suggested that miR-101 has significant roles in the development and radiosensitivity of NPC.

Previous studies have indicated that numerous miRNAs may function as oncogenes, for example miR-155 and miR-21 (22,23), or as tumor suppressors, including the miR-200 family and let-7 (24,25). A loss of miR-101 expression is frequently observed in certain types of human cancer and is associated with therapeutic resistance, which suggests that miR-101 may act as a tumor suppressor (18). In the present study, it was demonstrated that miR-101 was downregulated in NPC cell lines and that the ectopic expression of miR-101 significantly suppressed NPC-cell viability and enhanced their radiosensitivity. This further supported the hypothesized anti-tumor effects of miR-101 in NPC.

A study by Frankel et al (7) indicated that miR-101 may act as an inhibitor of autophagy, a catabolic pathway which involves self-degradation and the recycling of macromolecules and cellular organelles. This mechanism has been shown to be a critical adaptive response for tumor cell-survival under stressful conditions, including hypoxia, chemotherapy, radiotherapy or nutrient deprivation, which results in therapeutic resistance (26). Studies have also suggested that blocking autophagy may enhance NPC radiosensitivity (27). In the present study, it was demonstrated that expression of miR-101 was increased in response to IR. This behavior may be an adaptive feedback response to regulate autophagy.

miRNAs mainly regulate their target gene expression via translational repression, mRNA degradation or both (3). Several targets of miR-101, such as histone-lysine N-methyltransferase (28) and ATM (29), have been identified. In the present study, a luciferase reporter gene assay verified STMN1 as a direct target of miR-101. In addition, the overexpression of STMN1 significantly reduced the mRNA and protein expression of STMN1. Further investigation is required to elucidate the association between miR-101-mediated autophagy and the radiosensitivity of NPC.
In conclusion, the results of the present study indicated that the downregulation of miR-101 in NPC cell lines and ectopic expression of miR-101 suppressed the cell viability and enhanced the radiosensitivity of NPC cells by directly targeting STMN1. This identified an miR-101/STMN1 pathway which may contribute to the elucidation of the molecular mechanisms by which miR-101 regulates the radiosensitivity of NPC cells. Further investigation will be performed to determine whether miR-101-enhanced radiosensitivity is correlated with the inhibition of autophagy in NPC.

Acknowledgements

The authors would like to thank Professor Xia Yunfei for providing the nasopharyngeal carcinoma cell lines. This study was supported by the National Natural Science Foundation of China Grant (nos. 81272508, 81172243 and 81201961) and the Guangdong Natural Science Foundation (no. S201104000345).

References

1. Wei WI and Sham JS: Nasopharyngeal carcinoma. Lancet 365: 2041-2054, 2005.
2. Lo KW, Chung GT and To KF: Deciphering the molecular genetic basis of NPC through molecular, cytogenetic, and epigenetic approaches. Semin Cancer Biol 22: 79-86, 2012.
3. Feng XP, Yi H, Li MY, Li XH, Yi B, Zhang PF, Li C, Peng F, Tang CE, Li JL, et al: Identification of biomarkers for predicting nasopharyngeal carcinoma response to radiotherapy by proteomics. Cancer Res 70: 3450-3462, 2010.
4. Lai SZ, Li WF, Chen L, Luo W, Chen Y, Liu LZ, Sun Y, Liu AH, Liu MZ and Ma J: How does intensity-modulated radiotherapy versus conventional two-dimensional radiotherapy influence the treatment results in nasopharyngeal carcinoma patients? Int J Radiat Oncol Biol Phys 80: 661-668, 2011.
5. Gupta AK, McKenna WG, Weber CN, Feldman MD, Goldsmith JD, Rick R, Machaty M, Rosenthal DI, Bakanauskas VJ, Cerniglia GJ, et al: Local recurrence in head and neck cancer: relationship to radiation resistance and signal transduction. Clin Cancer Res 8: 118-127, 2002.
6. Kim VN, Nam J and Siomi MC: Biogenesis of small RNAs in animals. Nat Rev Mol Cell Biol 10: 126-136, 2009.
7. Frankel LB, Wen J, Lees M, Hoyer-Hansen M, Farkas T, Krogh A, Jaattela M and Lund AH: microRNA-101 is a potent inhibitor of autophagy. EMBO J 30: 4628-4636, 2011.
8. Bartel DP: microRNAs: genomics, biogenesis, mechanism, and function. Cell 116: 281-297, 2004.
9. Esquela-Kerscher A and Slack FJ: Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer 6: 259-269, 2006.
10. O’Day E and Lal A: MicroRNAs and their target gene networks in breast cancer. Breast Cancer Res 12: 201, 2010.
11. Zheng J, Deng J, Xiao M, Yang L, Zhang L, You Y, Hu M, Li N, Wu H, Li W, et al: A sequence polymorphism in miR-608 predicts recurrence after radiotherapy for nasopharyngeal carcinoma. Cancer Res 73: 5151-5162, 2013.
12. Zhang JX, Qian D, Wang FW, Liao DZ, Wei JH, Tong ZT, Fu J, Huang XX, Liao YJ, Deng HX, et al: microRNA-29c enhances the sensitivities of human nasopharyngeal carcinoma to cisplatin-based chemotherapy and radiotherapy. Cancer Lett 329: 91-98, 2013.
13. He XP, Shao Y, Li XL, Xu W, Chen GS, Sun HH, Xu HC, Xu X, Tang D, Zheng XF, et al: Downregulation of miR-101 in gastric cancer correlates with cyclooxygenase-2 overexpression and tumor growth. FEBS J 279: 4201-4212, 2012.
14. Luo L, Zhang T, Liu H, Lv T, Yuan D, Yao Y, Lv Y and Song Y: miR-101 and Mel-1 in non-small-cell lung cancer: expression profile and clinical significance. Med Oncol 29: 1681-1686, 2012.
15. Schee K, Bøy K, Abrahamsen TW, Fodstad Ø and Flåtmak K: Clinical relevance of microRNA miR-21, miR-31, miR-92a, miR-101, miR-106a and miR-145 in colorectal cancer. BMC Cancer 12: 505, 2012.
16. Wang R, Wang HB, Hao CJ, Cui Y, Han XC, Hu Y, Li FF, Xiao HF and Ma X: miR-101 is involved in human breast carcinogenesis by targeting Stathmin1. PLoS One 7: e46173, 2012.
17. Zhang J, Han C, Zhu H, Song K and Wu T: miR-101 inhibits cholangiocarcinoma angiogenesis through targeting vascular endothelial growth factor (VEGF). Am J Pathol 182: 1629-1639, 2013.
18. Chen S, Wang H, Ng WL, Curran WJ and Wang Y: Radiosensitizing effects of ectopic miR-101 on non-small-cell lung cancer cells depend on the endogenous miR-101 level. Int J Radiat Oncol Biol Phys 81: 1524-1529, 2011.
19. Green LM, Reade JL and Ware CF: Rapid colorimetric assay for cell viability: application to the quantitation of cytotoxicity and growth inhibition lymphokines. J Immunol Methods 70: 257-268, 1984.
20. Xie G, Zhan J, Tian Y, Liu Y, Chen Z, Ren C, Sun Q, Lian J, Chen L, Ruan J, et al: Mammosphere cells from high-passage MCF7 cell line show variable loss of tumorigenicity and radioresistance. Cancer Lett 316: 53-61, 2012.
21. Mah LJ, El-Osta A and Karagiannis TC: gammaH2AX: a sensitive molecular marker of DNA damage and repair. Leukemia 24: 679-686, 2010.
22. Wang W, He L, Richards EL, Challa S, Xu CX, Pernuth-Wey J, Lancaster JM, Coppola D, Sellers TA, Djeu JY and Cheng JQ: Upregulation of microRNA-155 promotes tumour angiogenesis by targeting VHL and is associated with poor prognosis and triple-negative breast cancer. Oncogene 33: 679-689, 2014.
23. Oue N, Anami K, Schetter AJ, Moehler M, Okayama H, Khan MA, Bowman ED, Mueller A, Schad A, Shimomura M, et al: High miR-21 expression from FFPE tissues is associated with poor survival and response to adjuvant chemotherapy in colon cancer. Int J Cancer 134: 1926-1934, 2014.
24. Schliekelman MJ, Gibbons DL, Faca VM, Creighton CJ, Rizvi ZH, Zhang Q, Wong CH, Wang H, Ungewiss C, Ahn YH, et al: Targets of the tumor suppressor miR-200 in regulation of the epithelial-mesenchymal transition in cancer. Cancer Res 71: 7670-7682, 2011.
25. Hu X, Guo J, Zheng L, Li C, Zheng TM, Tanyi JL, Liang S, Benedetto C, Mitidieri M, Katsaros D, Zhao X, Zhang Y and Huang Q and Zhang L: The heterochronous microRNA let-7 inhibits cell motility by regulating the genes in the actin cytoskeleton pathway in breast cancer. Mol Cancer Res 11: 240-250, 2013.
26. Choi AM, Ryter SW and Levine B: Autophagy in human health and disease. N Engl J Med 368: 651-662, 2013.
27. Wang Y, Yin W and Zhu X: Blocked autophagy enhances radiosensitivity of nasopharyngeal carcinoma cell line CNE-2 in vitro. Acta Otologyeargy 134: 105-110, 2014.
28. Luo C, Merz PR, Chen Y, Dickes E, Pscherer A, Schadendorf D and Eichmüller SB: miR-101 inhibits melanoma cell invasion and proliferation by targeting MITF and EZH2. Cancer Lett 341: 240-247, 2013.
29. Yan D, Ng WL and Zhang X, Wang P, Zhang Z, Mo YY, Mao H, Hao CI, Olson JJ, Curran WJ and Wang Y: Targeting DNA-PKcs and ATM with miR-101 sensitizes tumors to radiation. PLoS One 5: e11397, 2010.
30. Wiek E, Birkenland E, Trovik J, Werner HM, Hoivik EA, Mjös S, Krakstad C, Kusonmano K, Mautland K, Stathmin(MS3), et al: High phospho-Stathmin(Serine38) expression identifies aggressive endometrial cancer and suggests an association with PI3K inhibition. Clin Cancer Res 19: 2331-2341, 2013.